165 results on '"Brun JG"'
Search Results
2. SAT0270 Ultrasonography of major salivary glands in juvenile sjÖgren's syndrome – preliminary findings in a multi-center study
- Author
-
Hammenfors, DS, primary, Valim, V, additional, Bica, B, additional, Pasoto, SG, additional, Lilleby, V, additional, Nieto-González, JC, additional, Silva, CA, additional, Mossel, E, additional, Pereira, RM, additional, Bootsma, H, additional, Brun, JG, additional, Jonsson, R, additional, and Jonsson, MV, additional
- Published
- 2017
- Full Text
- View/download PDF
3. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)
- Author
-
Seror, R, Bootsma, H, Saraux, A, Bowman, S, Theander, E, Brun, Jg, Baron, G, Le Guern, V, Devauchelle Pensec, V, Ramos Casals, M, Valim, V, Dörner, T, Tzioufas, A, Gottenberg, Je, Laqué, Rs, Mandl, T, Hachulla, E, Sivils, Kl, Wf, Ng, Fauchais, A, Bombardieri, S, Priori, R, BARTOLONI BOCCI, Elena, Goeb, V, Praprotnik, S, Sumida, T, Nishiyama, S, Caporali, R, Kruize, Aa, Vollenweider, C, Ravaud, P, Meiners, P, Brito Zerón, P, Vitali, C, Mariette, X, Gerli, Roberto, Kallenberg, C, De Vita, S, Demoulins, F, Montecucco, C, Tomsic, M, Scofield, H, Valesini, G., Service de rhumatologie, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Rheumatology, Lund University [Lund], Education Discours Apprentissages (EDA - EA 4071), Université Paris Descartes - Paris 5 (UPD5), Klinik für Dermatologie, Venerologie und Allergologie, Department of Pathophysiology, Medical School, University of Athens, Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lille, Droit et Santé, University of Northumbria at Newcastle [United Kingdom], Service de Médecine interne A et polyclinique médicale [CHU Limoges], CHU Limoges, Service de rhumatologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), University Medical Centre, University of Tsukuba, Equipe 5 : METHODS - Méthodes de l’évaluation thérapeutique des maladies chroniques (CRESS - U1153), Université Paris Descartes - Paris 5 (UPD5)-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Internal Medicine and section of Rheumatology, Villamarina Hospital, Immunologie des Maladies Virales et Autoimmunes (IMVA - U1184), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA), Service de rhumatologie [CHU Rouen], Université de Tsukuba = University of Tsukuba, Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA), Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Translational Immunology Groningen (TRIGR), Immunologie et Pathologie ( EA2216 ), Université de Brest ( UBO ) -IFR148, Centre d'Investigation Clinique ( CIC - Brest ), Université de Brest ( UBO ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Education Discours Apprentissages ( EDA - EA 4071 ), Université Paris Descartes - Paris 5 ( UPD5 ), Université de Strasbourg ( UNISTRA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), CHU Rouen-Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Equipe 5 : METHODS - Méthodes de l’évaluation thérapeutique des maladies chroniques ( CRESS - U1153 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité ( CRESS (U1153 / UMR_A 1125) ), Institut National de la Recherche Agronomique ( INRA ) -Université Sorbonne Paris Cité ( USPC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut National de la Recherche Agronomique ( INRA ) -Université Sorbonne Paris Cité ( USPC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Immunologie des Maladies Virales et Autoimmunes ( IMVA - U1184 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris-Sud - Paris 11 ( UP11 ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Sorbonne Paris Cité (USPC), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)
- Subjects
0301 basic medicine ,Genetics and Molecular Biology (all) ,Male ,[SDV]Life Sciences [q-bio] ,Health Status ,Rheumatology ,Immunology ,Biochemistry, Genetics and Molecular Biology (all) ,Immunology and Allergy ,Biochemistry ,Severity of Illness Index ,RESPONSIVENESS ,DOUBLE-BLIND ,0302 clinical medicine ,EUROPEAN LEAGUE ,Epidemiology ,Prospective Studies ,SYSTEMIC-LUPUS-ERYTHEMATOSUS ,10. No inequality ,Prospective cohort study ,Non-U.S. Gov't ,Research Support, Non-U.S. Gov't ,RANDOMIZED CONTROLLED-TRIAL ,Middle Aged ,3. Good health ,Sjogren's Syndrome ,[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system ,Patient Satisfaction ,Rheumatoid arthritis ,patient-reported indexes (ESSPRI) ,Disease Progression ,Female ,Symptom Assessment ,medicine.medical_specialty ,BELIMUMAB ,Research Support ,General Biochemistry, Genetics and Molecular Biology ,[ SDV.MHEP.RSOA ] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system ,03 medical and health sciences ,Diagnostic Self Evaluation ,Patient satisfaction ,Internal medicine ,[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology ,Severity of illness ,medicine ,Journal Article ,Humans ,disease activity states ,Aged ,030203 arthritis & rheumatology ,Outcomes research ,Patient perspective ,Sjøgren's Syndrome ,ROC Curve ,[ SDV ] Life Sciences [q-bio] ,EULAR primary Sjogren's syndrome disease activity ,business.industry ,RITUXIMAB TREATMENT ,medicine.disease ,EFFICACY ,RHEUMATOID-ARTHRITIS ,Clinical trial ,030104 developmental biology ,Physical therapy ,business ,ACCEPTABLE SYMPTOM STATE ,Rheumatism ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience; OBJECTIVES: To define disease activity levels, minimal clinically important improvement (MCII) and patient-acceptable symptom state (PASS) with the primary Sjogren's syndrome (SS) disease activity indexes: European League Against Rheumatism (EULAR) SS disease activity index (ESSDAI) and EULAR SS patient-reported index (ESSPRI). METHODS: For 790 patients from two large prospective cohorts, ESSDAI, physician evaluation of disease activity, ESSPRI and patients' satisfaction with their current health status were recorded. Receiver operating characteristic curve analyses and anchoring methods were used to estimate disease activity levels of ESSDAI and the PASS of ESSPRI. At follow-up visit, patients and physicians assessed, respectively, whether symptoms and disease activity have improved or not. An anchoring method based on this evaluation was used to estimate MCII of ESSDAI and ESSPRI. RESULTS: Low-activity (ESSDAI/=14) levels were defined. MCII of ESSDAI was defined as an improvement of at least three points. The PASS estimate was defined as an ESSPRI/=5) and define response to treatment as an improvement of ESSDAI at least three points. For addressing patient-reported outcomes, inclusion of patients with unsatisfactory symptom state (ESSPRI>/=5) and defining response as an improvement of ESSPRI at least one point or 15% seems reasonable.
- Published
- 2014
- Full Text
- View/download PDF
4. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). in combination wiIh methotrexate
- Author
-
Gseror, R, Bootsma, H, Saraux, A, Bowman, Sj, Theander, E, Brun, Jg, Baron, G, Le Guern, V, Devauchelle Pensec, V, Ramos Casals, M, Valim, V, Dörner, T, Tzioufas, A, Gottenberg, Je, Solans Laqué, R, Mandl, T, Hachulla, E, Sivils, Kl, Ng, Wf, Fauchais, Al, Bombardieri, Stefano, Priori, R, Bartoloni, E, Goeb, V, Praprotnik, S, Sumida, T, Nishiyama, S, Caporali, R, Kruize, Aa, Vollenweider, C, Ravaud, P, Meiners, P, Brito Zerón, P, Vitali, C, and Mariette, X.
- Published
- 2014
5. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab
- Author
-
Nordal, HH, primary, Brun, JG, additional, Hordvik, M, additional, Eidsheim, M, additional, Jonsson, R, additional, and Halse, A-K, additional
- Published
- 2016
- Full Text
- View/download PDF
6. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome
- Author
-
Seror, R, Ravaud, P, Bowman, Sj, Baron, G, Tzioufas, A, Theander, E, Gottenberg, Je, Bootsma, H, Mariette, X, Vitali, C, Asmussen, K, Jacobsen, S, Bijlsma, Jw, Kruize, Aa, Bombardieri, S, Bookman, A, Kallenberg, C, Brun, Jg, Jonsson, R, Carsons, S, DE VITA, Salvatore, Del Papa, N, Devauchelle, V, Dörner, T, Gerli, R, Sibilia, J, Hachulla, E, Illei, G, Isenberg, D, Jones, A, Manoussakis, M, Montecucco, C, Omdal, R, Parke, A, Praprotnik, S, Tomsic, M, Price, E, Casals, Mr, Smolen, J, Steinfeld, S, Sutcliffe, N, Jacobsson, L, Valesini, G, Vivino, F. B., Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Immunologie antivirale systémique et cérébrale, Université Paris-Sud - Paris 11 (UP11)-IFR93-Institut National de la Santé et de la Recherche Médicale (INSERM), Rheumatology department, University Hospital Birmingham-NHS Foundation Trust, Department of pathophysiology, Department of Rheumatology, Lund University [Lund], Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Department of Rheumatology and Clinical Immunology, UMCG, Service de rhumatologie, Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Department of Internal Medicine and section of Rheumatology, Villamarina Hospital, Translational Immunology Groningen (TRIGR), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, and Gillet, Catherine
- Subjects
Male ,Systemic disease ,Placebo-controlled study ,systemic features ,primary Sjogren's syndrome ,PLACEBO-CONTROLLED TRIAL ,Severity of Illness Index ,DOUBLE-BLIND ,0302 clinical medicine ,LYMPHOMA ,Immunology and Allergy ,Medicine ,VASCULITIS ,Observer Variation ,0303 health sciences ,outcome assessment, systemic features, activity index, clinical vignettes ,disease activity ,Middle Aged ,3. Good health ,Peeling skin syndrome ,Sjogren's Syndrome ,AGREEMENT ,Cohort ,Female ,ACTIVITY SCORE ,Adult ,medicine.medical_specialty ,Immunology ,Article ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Rheumatology ,Internal medicine ,Severity of illness ,REGRESSION ,LUPUS-ERYTHEMATOSUS ,Humans ,COHORT ,outcome assessment ,Aged ,030304 developmental biology ,030203 arthritis & rheumatology ,Lupus erythematosus ,business.industry ,activity index ,Reproducibility of Results ,RITUXIMAB TREATMENT ,medicine.disease ,Clinical trial ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Physical therapy ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business ,Rheumatism ,clinical vignettes - Abstract
ObjectiveTo develop a disease activity index for patients with primary Sjögren's syndrome (SS): the European League Against Rheumatism (EULAR) Sjögren's syndrome disease activity index (ESSDAI).MethodsThirty-nine SS experts participated in an international collaboration, promoted by EULAR, to develop the ESSDAI. Experts identified 12 organ-specific ‘domains’ contributing to disease activity. For each domain, features of disease activity were classified in three or four levels according to their severity. Data abstracted from 96 patients with systemic complications of primary SS were used to generate 702 realistic vignettes for which all possible systemic complications were represented. Using the 0–10 physician global assessment (PhGA) scale, each expert scored the disease activity of five patient profiles and 20 realistic vignettes. Multiple regression modelling, with PhGA used as the dependent variable, was used to estimate the weight of each domain.ResultsAll 12 domains were significantly associated with disease activity in the multivariate model, domain weights ranged from 1 to 6. The ESSDAI scores varied from 2 to 47 and were significantly correlated with PhGA for both real patient profiles and realistic vignettes (r=0.61 and r=0.58, respectively, pConclusionsThe ESSDAI is a clinical index designed to measure disease activity in patients with primary SS. Once validated, such a standardised evaluation of primary SS should facilitate clinical research and be helpful as an outcome measure in clinical trials.
- Published
- 2010
- Full Text
- View/download PDF
7. Calprotectin (S100A8/A9), S100A12, and EDTA-resistant S100A12 complexes (ERAC) in primary Sjögren’s syndrome
- Author
-
Nordal, HH, primary, Brun, JG, additional, Halse, A-K, additional, Madland, TM, additional, Fagerhol, MK, additional, and Jonsson, R, additional
- Published
- 2013
- Full Text
- View/download PDF
8. The point prevalence of clinically relevant primary Sjögren's syndrome in two Norwegian counties
- Author
-
Gøransson, LG, primary, Haldorsen, K, additional, Brun, JG, additional, Harboe, E, additional, Jonsson, MV, additional, Skarstein, K, additional, Time, K, additional, and Omdal, R, additional
- Published
- 2011
- Full Text
- View/download PDF
9. Salivary gland and temporomandibular joint involvement in rheumatoid arthritis: relation to disease activity
- Author
-
Moen, K, primary, Bertelsen, LT, additional, Hellem, S, additional, Jonsson, R, additional, and Brun, JG, additional
- Published
- 2005
- Full Text
- View/download PDF
10. OP0068 SjÖgren’s syndrome in an out-patient clinic: classification of patients according to the preliminary european criteria and the proposed modified european criteria
- Author
-
Brun, JG, primary, Madland, TM, additional, Gjesdal, CB, additional, and Bertelsen, LT, additional
- Published
- 2001
- Full Text
- View/download PDF
11. THU0170 Immunoglobulin g fc-receptor (fcgr) iiia polymorphisms and disease expression in rheumatoid arthritis
- Author
-
Brun, JG, primary, Madland, TM, additional, and Vedeler, CA, additional
- Published
- 2001
- Full Text
- View/download PDF
12. Association between genetic variants in the tumour necrosis factor/lymphotoxin [alpha]/lymphotoxin [beta] locus and primary Sjogren's syndrome in Scandinavian samples.
- Author
-
Bolstad AI, Le Hellard S, Kristjansdottir G, Vasaitis L, Kvarnström M, Sjöwall C, Johnsen SJ, Eriksson P, Omdal R, Brun JG, Wahren-Herlenius M, Theander E, Syvänen AC, Rönnblom L, Nordmark G, and Jonsson R
- Published
- 2012
- Full Text
- View/download PDF
13. Large molecular size EDTA-resistant complexes containing S100A12, ERAC, in serum during inflammatory conditions.
- Author
-
Fagerhol MK, Larsen A, Brun JG, Hammer HB, Angel K, Kvien TK, Kinne I, and Madland TM
- Published
- 2012
14. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome.
- Author
-
Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, Ramos-Casals M, Dörner T, Bombardieri S, Hachulla E, Brun JG, Kruize AA, Praprotnik S, Tomsic M, Gottenberg JE, Devauchelle V, Devita S, Vollenweider C, Mandl T, and Tzioufas A
- Abstract
Objectives: To develop a score for assessment of patients' symptoms in primary Sjögren's syndrome (SS): the EULAR SS Patient Reported Index (ESSPRI).Methods: Dryness, pain, somatic and mental fatigue were identified as the main symptoms of patients with primary SS, in studies developing the Profile of Fatigue and Discomfort (PROFAD) and Sicca Symptoms Inventory (SSI). It was suspected that a single 0-10 numerical scale for each domain was sufficient to assess these symptoms. These four scales were gathered to form the ESSPRI. 230 patients, from 12 countries completed the ESSPRI, SSI and PROFAD questionnaires and a 0-10 patient global assessment (PGA). Correlations between each symptom and PGA were obtained. Multiple regression modelling, using PGA as 'gold standard' was used to select domains and estimate their weights.Results: PGA had good correlation with dryness, limb pain, fatigue and mental fatigue (r=0.49-0.59, all p<0.0001), but correlated less well with individual dryness features. In multivariate analysis, dryness, limb pain and fatigue, but not mental fatigue, were significantly associated with PGA; weights derived from the regression were identical for these three domains. Thus, ESSPRI was redefined as the mean of the three scales: dryness, limb pain and fatigue. Lastly, ESSPRI significantly correlated with PGA (r=0.70), PROFAD (r=0.73) and SSI (r=0.66).Conclusion: ESSPRI is a very simple index designed to measure patients' symptoms in primary SS. It has good construct validity and is well correlated with SSI and PROFAD. ESSPRI should now be validated for use as an outcome measure in clinical trials. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
15. Levels of plasmacytoid dendritic cells and type-2 myeloid dendritic cells are reduced in peripheral blood of patients with primary Sjogren's syndrome.
- Author
-
Vogelsang P, Brun JG, Oijordsbakken G, Skarstein K, Jonsson R, and Appel S
- Published
- 2010
- Full Text
- View/download PDF
16. S100 proteins calprotectin and S100A12 are related to radiographic changes rather than disease activity in psoriatic arthritis with low disease activity.
- Author
-
Madland TM, Larsen A, Brun JG, Madland, Tor Magne, Larsen, Annette, and Brun, Johan G
- Published
- 2007
17. Serological implications of germinal center-like structures in primary Sjögren's syndrome.
- Author
-
Jonsson MV, Skarstein K, Jonsson R, and Brun JG
- Published
- 2007
18. Calprotectin (S100A8/A9), S100A12, and EDTA-resistant S100A12 complexes (ERAC) in primary Sjögren's syndrome.
- Author
-
Nordal, HH, Brun, JG, Halse, A-K, Madland, TM, Fagerhol, MK, and Jonsson, R
- Subjects
- *
SJOGREN'S syndrome , *ETHYLENEDIAMINETETRAACETIC acid , *PROTEIN analysis , *NEUTROPHILS , *PATIENTS - Abstract
The article focuses on a study related to the evaluation of calprotectin, S100A12 protein and ethylenediaminetetraacetic acid (EDTA)-resistant S100A12 complexes (ERAC) in patients with primary Sjögren's syndrome (pSS). As per the study, 141 patients who fulfill pSS criteria by the American–European Consensus Group were used. The study discusses the correlation between calprotectin and S100A12 with neutrophil.
- Published
- 2014
- Full Text
- View/download PDF
19. Potential association of muscarinic receptor 3 gene variants with primary Sjogren's syndrome.
- Author
-
Appel S, Le Hellard S, Bruland O, Brun JG, Omdal R, Kristjansdottir G, Theander E, Nordmark G, Kvarnström M, Eriksson P, Rönnblom L, Wahren-Herlenius M, and Jonsson R
- Published
- 2011
- Full Text
- View/download PDF
20. Genetic association between methyl-CpG binding protein 2 (MECP2) and primary Sjogren's syndrome.
- Author
-
Cobb BL, Fei Y, Jonsson R, Bolstad AI, Brun JG, Rischmueller M, Lester SE, Witte T, Illei G, Brennan M, Bowman S, Moser KL, Harley JB, Sawalha AH, Cobb, Beth L, Fei, Yiping, Jonsson, Roland, Bolstad, Anne Isine, Brun, Johan G, and Rischmueller, Maureen
- Published
- 2010
- Full Text
- View/download PDF
21. Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland.
- Author
-
Wiley MM, Khatri B, Joachims ML, Tessneer KL, Stolarczyk AM, Rasmussen A, Anaya JM, Aqrawi LA, Bae SC, Baecklund E, Björk A, Brun JG, Bucher SM, Dand N, Eloranta ML, Engelke F, Forsblad-d'Elia H, Fugmann C, Glenn SB, Gong C, Gottenberg JE, Hammenfors D, Imgenberg-Kreuz J, Jensen JL, Johnsen SJA, Jonsson MV, Kelly JA, Khanam S, Kim K, Kvarnström M, Mandl T, Martín J, Morris DL, Nocturne G, Norheim KB, Olsson P, Palm Ø, Pers JO, Rhodus NL, Sjöwall C, Skarstein K, Taylor KE, Tombleson P, Thorlacius GE, Venuturupalli S, Vital EM, Wallace DJ, Grundahl KM, Radfar L, Brennan MT, James JA, Scofield RH, Gaffney PM, Criswell LA, Jonsson R, Appel S, Eriksson P, Bowman SJ, Omdal R, Rönnblom L, Warner BM, Rischmueller M, Witte T, Farris AD, Mariette X, Shiboski CH, Wahren-Herlenius M, Alarcón-Riquelme ME, Ng WF, Sivils KL, Guthridge JM, Adrianto I, Vyse TJ, Tsao BP, Nordmark G, and Lessard CJ
- Abstract
Fine mapping and bioinformatic analysis of the DDX6-CXCR5 genetic risk association in Sjögren's Disease (SjD) and Systemic Lupus Erythematosus (SLE) identified five common SNPs with functional evidence in immune cell types: rs4938573, rs57494551, rs4938572, rs4936443, rs7117261. Functional interrogation of nuclear protein binding affinity, enhancer/promoter regulatory activity, and chromatin-chromatin interactions in immune, salivary gland epithelial, and kidney epithelial cells revealed cell type-specific allelic effects for all five SNPs that expanded regulation beyond effects on DDX6 and CXCR5 expression. Mapping the local chromatin regulatory network revealed several additional genes of interest, including lnc-PHLDB1-1 . Collectively, functional characterization implicated the risk alleles of these SNPs as modulators of promoter and/or enhancer activities that regulate cell type-specific expression of DDX6 , CXCR5 , and lnc-PHLDB1-1 , among others. Further, these findings emphasize the importance of exploring the functional significance of SNPs in the context of complex chromatin architecture in disease-relevant cell types and tissues., Competing Interests: Competing Interests C.J.L.* and A.D.F. have an active collaborative research agreement with Janssen. E.B. has an active research collaboration with Pfizer. T.M. is employed as medical solutions lead in rheumatology at UCB. R.H.S. is a consultant for Jansen Pharmaceuticals. S.J.B. provided consultancy services for Abbvie, BMS, Galapagos, Iqvia, J&J, Kiniksa, and Novartis in 2020–2021. L.R. provided consultancy services for AstraZeneca. B.M.W. has active collaborative research agreements with Astellas Bio and Pfizer, Inc. M.R. received grants from Amgen, AstraZeneca, Bristol Myers-Squibb, Novartis, and Servier for clinical trials in Sjögren’s Syndrome and SLE. All other authors have reported that they have no competing interests to report.
- Published
- 2023
- Full Text
- View/download PDF
22. Author Correction: Genome-wide association study identifies Sjögren's risk loci with functional implications in immune and glandular cells.
- Author
-
Khatri B, Tessneer KL, Rasmussen A, Aghakhanian F, Reksten TR, Adler A, Alevizos I, Anaya JM, Aqrawi LA, Baecklund E, Brun JG, Bucher SM, Eloranta ML, Engelke F, Forsblad-d'Elia H, Glenn SB, Hammenfors D, Imgenberg-Kreuz J, Jensen JL, Johnsen SJA, Jonsson MV, Kvarnström M, Kelly JA, Li H, Mandl T, Martín J, Nocturne G, Norheim KB, Palm Ø, Skarstein K, Stolarczyk AM, Taylor KE, Teruel M, Theander E, Venuturupalli S, Wallace DJ, Grundahl KM, Hefner KS, Radfar L, Lewis DM, Stone DU, Kaufman CE, Brennan MT, Guthridge JM, James JA, Scofield RH, Gaffney PM, Criswell LA, Jonsson R, Eriksson P, Bowman SJ, Omdal R, Rönnblom L, Warner B, Rischmueller M, Witte T, Farris AD, Mariette X, Alarcon-Riquelme ME, Shiboski CH, Wahren-Herlenius M, Ng WF, Sivils KL, Adrianto I, Nordmark G, and Lessard CJ
- Published
- 2023
- Full Text
- View/download PDF
23. Author Correction: Genome-wide association study identifies Sjögren's risk loci with functional implications in immune and glandular cells.
- Author
-
Khatri B, Tessneer KL, Rasmussen A, Aghakhanian F, Reksten TR, Adler A, Alevizos I, Anaya JM, Aqrawi LA, Baecklund E, Brun JG, Bucher SM, Eloranta ML, Engelke F, Forsblad-d'Elia H, Glenn SB, Hammenfors D, Imgenberg-Kreuz J, Jensen JL, Johnsen SJA, Jonsson MV, Kvarnström M, Kelly JA, Li H, Mandl T, Martín J, Nocturne G, Norheim KB, Palm Ø, Skarstein K, Stolarczyk AM, Taylor KE, Teruel M, Theander E, Venuturupalli S, Wallace DJ, Grundahl KM, Hefner KS, Radfar L, Lewis DM, Stone DU, Kaufman CE, Brennan MT, Guthridge JM, James JA, Scofield RH, Gaffney PM, Criswell LA, Jonsson R, Eriksson P, Bowman SJ, Omdal R, Rönnblom L, Warner B, Rischmueller M, Witte T, Farris AD, Mariette X, Alarcon-Riquelme ME, Shiboski CH, Wahren-Herlenius M, Ng WF, Sivils KL, Adrianto I, Nordmark G, and Lessard CJ
- Published
- 2022
- Full Text
- View/download PDF
24. Aberrant signaling of immune cells in Sjögren's syndrome patient subgroups upon interferon stimulation.
- Author
-
Sarkar I, Davies R, Aarebrot AK, Solberg SM, Petrovic A, Joshi AM, Bergum B, Brun JG, Hammenfors D, Jonsson R, and Appel S
- Subjects
- Female, Humans, Interferon-alpha metabolism, Signal Transduction physiology, T-Lymphocytes metabolism, Leukocytes, Mononuclear metabolism, Sjogren's Syndrome
- Abstract
Background: Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease, characterized by mononuclear cell infiltrates in the salivary and lacrimal glands, leading to glandular atrophy and dryness. Patient heterogeneity and lack of knowledge regarding its pathogenesis makes pSS a difficult disease to manage., Methods: An exploratory analysis using mass cytometry was conducted of MAPK/ERK and JAK/STAT signaling pathways in peripheral blood mononuclear cells (PBMC) from 16 female medication free pSS patients (8 anti-Sjögren's syndrome-related antigen A negative/SSA- and 8 SSA+) and 8 female age-matched healthy donors after stimulation with interferons (IFNs)., Results: We found significant differences in the frequencies of memory B cells, CD8+ T central and effector memory cells and terminally differentiated CD4+ T cells among the healthy donors and patient subgroups. In addition, we observed an upregulation of HLA-DR and CD38 in many cell subsets in the patients. Upon IFNα2b stimulation, slightly increased signaling through pSTAT1 Y701 was observed in most cell types in pSS patients compared to controls, while phosphorylation of STAT3 Y705 and STAT5 Y694 were slightly reduced. IFNγ stimulation resulted in significantly increased pSTAT1 Y701 induction in conventional dendritic cells (cDCs) and classical and non-classical monocytes in the patients. Most of the observed differences were more prominent in the SSA+ subgroup, indicating greater disease severity in them., Conclusions: Augmented activation status of certain cell types along with potentiated pSTAT1 Y701 signaling and reduced pSTAT3 Y705 and pSTAT5 Y694 induction may predispose pSS patients, especially the SSA+ subgroup, to upregulated expression of IFN-induced genes and production of autoantibodies. These patients may benefit from therapies targeting these pathways., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Sarkar, Davies, Aarebrot, Solberg, Petrovic, Joshi, Bergum, Brun, Hammenfors, Jonsson and Appel.)
- Published
- 2022
- Full Text
- View/download PDF
25. Genome-wide association study identifies Sjögren's risk loci with functional implications in immune and glandular cells.
- Author
-
Khatri B, Tessneer KL, Rasmussen A, Aghakhanian F, Reksten TR, Adler A, Alevizos I, Anaya JM, Aqrawi LA, Baecklund E, Brun JG, Bucher SM, Eloranta ML, Engelke F, Forsblad-d'Elia H, Glenn SB, Hammenfors D, Imgenberg-Kreuz J, Jensen JL, Johnsen SJA, Jonsson MV, Kvarnström M, Kelly JA, Li H, Mandl T, Martín J, Nocturne G, Norheim KB, Palm Ø, Skarstein K, Stolarczyk AM, Taylor KE, Teruel M, Theander E, Venuturupalli S, Wallace DJ, Grundahl KM, Hefner KS, Radfar L, Lewis DM, Stone DU, Kaufman CE, Brennan MT, Guthridge JM, James JA, Scofield RH, Gaffney PM, Criswell LA, Jonsson R, Eriksson P, Bowman SJ, Omdal R, Rönnblom L, Warner B, Rischmueller M, Witte T, Farris AD, Mariette X, Alarcon-Riquelme ME, Shiboski CH, Wahren-Herlenius M, Ng WF, Sivils KL, Adrianto I, Nordmark G, and Lessard CJ
- Subjects
- Genetic Predisposition to Disease, Humans, Polymorphism, Single Nucleotide, Genome-Wide Association Study, Sjogren's Syndrome genetics
- Abstract
Sjögren's disease is a complex autoimmune disease with twelve established susceptibility loci. This genome-wide association study (GWAS) identifies ten novel genome-wide significant (GWS) regions in Sjögren's cases of European ancestry: CD247, NAB1, PTTG1-MIR146A, PRDM1-ATG5, TNFAIP3, XKR6, MAPT-CRHR1, RPTOR-CHMP6-BAIAP6, TYK2, SYNGR1. Polygenic risk scores yield predictability (AUROC = 0.71) and relative risk of 12.08. Interrogation of bioinformatics databases refine the associations, define local regulatory networks of GWS SNPs from the 95% credible set, and expand the implicated gene list to >40. Many GWS SNPs are eQTLs for genes within topologically associated domains in immune cells and/or eQTLs in the main target tissue, salivary glands., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
26. Impaired activation of STAT5 upon IL-2 stimulation in Tregs and elevated sIL-2R in Sjögren's syndrome.
- Author
-
Keindl M, Davies R, Bergum B, Brun JG, Hammenfors D, Jonsson R, Lyssenko V, and Appel S
- Subjects
- Cross-Sectional Studies, Female, Humans, Receptors, Interleukin-2 metabolism, T-Lymphocytes, Regulatory, Tumor Suppressor Proteins, Interleukin-2 pharmacology, STAT5 Transcription Factor metabolism, Sjogren's Syndrome
- Abstract
Background: Interleukin-2 (IL-2) and the high-affinity IL-2 receptor (IL-2R) are essential for the survival of regulatory T cells (Tregs) which are the main players in immune tolerance and prevention of autoimmune diseases. Sjögren's syndrome (SS) is a chronic autoimmune disease predominantly affecting women and is characterised by sicca symptoms including oral and ocular dryness. The aim of this study was to investigate an association between IL-2R and Treg function in patients with SS of different severity defined by the salivary flow rate., Methods: In a cross-sectional study, we determined plasma soluble IL-2R (sIL-2R) levels in women with SS (n=97) and healthy females (n=50) using ELISA. A subset of those (n=51) was screened for Treg function measured by the STAT5 signalling response to IL-2 using phospho-flow cytometry., Results: We found that elevated plasma levels of sIL-2R were positively associated with the severity of SS reflected by a pathologically low salivary flow. Phospho-flow analysis revealed that patients with SS have a significantly lower frequency of pSTAT5
+ Tregs upon IL-2 stimulation compared with healthy individuals, while the frequency of Tregs and pSTAT5 in conventional T cells remained unchanged. In addition, we observed more pSTAT5+ Tregs at baseline in patients with SS, which is significantly associated with seropositivity and elevated sIL-2R., Conclusions: Our data indicates that Tregs have a weakened immunosuppressive function in patients with SS due to impaired IL-2/IL-2R signalling capacity. This could mediate lymphocytic infiltration into salivary glands inducing sicca symptoms. We believe that sIL-2R could act as a useful indicator for SS and disease severity., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
27. Genetic variants at the RTP4/MASP1 locus are associated with fatigue in Scandinavian patients with primary Sjögren's syndrome.
- Author
-
Norheim KB, Imgenberg-Kreuz J, Alexsson A, Johnsen SJA, Bårdsen K, Brun JG, Dehkordi RK, Theander E, Mandl T, Jonsson R, Ng WF, Lessard CJ, Rasmussen A, Sivilis K, Ronnblom L, and Omdal R
- Subjects
- Alleles, Cohort Studies, Fatigue epidemiology, Fatigue genetics, Genome-Wide Association Study, Humans, Mannose-Binding Protein-Associated Serine Proteases, Sjogren's Syndrome complications, Sjogren's Syndrome genetics
- Abstract
Objectives: Fatigue is common and severe in primary Sjögren's syndrome (pSS). The aim of this study was to identify genetic determinants of fatigue in pSS through a genome-wide association study., Methods: Patients with pSS from Norway, Sweden, UK and USA with fatigue and genotype data available were included. After genotype imputation and quality control, 682 patients and 4 966 157 genetic markers were available. Association analysis in each cohort using linear regression with fatigue as a continuous variable and meta-analyses between the cohorts were performed., Results: Meta-analysis of the Norwegian and Swedish cohorts identified five polymorphisms within the same linkage disequilibrium block at the receptor transporter protein 4 ( RTP4)/MASP1 locus associated with fatigue with genome-wide significance (GWS) (p<5×10
-8 ). Patients homozygous for the major allele scored 25 mm higher on the fatigue Visual Analogue Scale than patients homozygous for the minor allele. There were no variants associated with fatigue with GWS in meta-analyses of the US/UK cohorts, or all four cohorts. RTP4 expression in pSS B cells was upregulated and positively correlated with the type I interferon score. Expression quantitative trait loci effects in whole blood for fatigue-associated variants at RTP4/MASP1 and levels of RTP4 and MASP1 expression were identified., Conclusion: Genetic variations at RTP4/MASP1 are associated with fatigue in Scandinavian pSS patients. RTP4 encodes a Golgi chaperone that influences opioid pain receptor function and MASP1 is involved in complement activation. These results add evidence for genetic influence over fatigue in pSS., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2021
- Full Text
- View/download PDF
28. Inflammatory Stratification in Primary Sjögren's Syndrome Reveals Novel Immune Cell Alterations in Patients' Minor Salivary Glands.
- Author
-
Bharaj TK, Aqrawi LA, Fromreide S, Jonsson R, Brun JG, Appel S, and Skarstein K
- Subjects
- Adipose Tissue immunology, Adipose Tissue pathology, CD4-Positive T-Lymphocytes immunology, CD4-Positive T-Lymphocytes pathology, Cross-Sectional Studies, Disease Progression, Female, Germinal Center immunology, Germinal Center pathology, Humans, Inflammation pathology, Male, Middle Aged, Salivary Glands, Minor pathology, Sjogren's Syndrome pathology, Inflammation immunology, Salivary Glands, Minor immunology, Sjogren's Syndrome immunology
- Abstract
There is a critical need to deconvolute the heterogeneity displayed by the minor salivary glands of primary Sjögren's syndrome (pSS) patients. This is challenging primarily because the disease etiology remains unknown. The hypothesis includes that initial events in the disease pathogenesis target the salivary glands, thereby triggering the development of focal infiltrates (≥50 mononuclear cells) and finally germinal center-like structures. However, the proportion of key mononuclear immune cells residing at these sites, in combination with the overall ratio of morphometric tissue atrophy and adipose infiltration within the minor salivary glands (MSG) parenchyma at distinct phases of inflammatory disease establishment and progression have not been quantified in detail. In this cross-sectional study, we intended to address this problem by stratifying 85 patients into mild (S1), moderate (S2), and severe (S3) stages using the Inflammatory severity index. We found that mild (<3%) and marked (≥3%) levels of atrophy were accompanied by the respective levels of adipose infiltration in the non-SS sicca controls ( p < 0.01), but not in pSS patients. The percentage of adipose infiltration significantly correlated with the age of patients ( r = 0.458, p < 0.0001) and controls ( r = 0.515, p < 0.0001). The CD4
+ T helper cell incidence was reduced in the focal infiltrates of the MSG of S2 patients compared to S1 ( p < 0.01), and in S2 compared to S1 and S3 combined ( p < 0.05). CD20+ B cells increased from S1 to S3 ( p < 0.01) and S2 to S3 ( p < 0.01), meanwhile CD138+ plasma cells diminished in S3 patients compared to both S1 and S2 groups combined ( p < 0.01). The proportion of patients with anti-Ro/SSA+ , anti-La/SSB+ , and RF+ increased over the course of inflammatory disease progression and they were significantly more common in the S3 group relative to S1 ( p < 0.05). On the other hand, S2 patients measured a higher mean salivary flow relative to S1 and S3 patients combined ( p < 0.05). Our results demonstrate how the proposed Inflammatory severity index stratification revealed pathological cell and tissue-associated aberrations in the salivary component over the course of inflammatory progression, and their correlations to clinical outcomes. This could be directly transferred to the optimization of available diagnostic strategies applied for pSS patients., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Bharaj, Aqrawi, Fromreide, Jonsson, Brun, Appel and Skarstein.)- Published
- 2021
- Full Text
- View/download PDF
29. Lipid, fatty acid, carnitine- and choline derivative profiles in rheumatoid arthritis outpatients with different degrees of periodontal inflammation.
- Author
-
Beyer K, Lie SA, Bjørndal B, Berge RK, Svardal A, Brun JG, and Bolstad AI
- Subjects
- Aged, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Outpatients, Arthritis, Rheumatoid metabolism, Carnitine metabolism, Choline metabolism, Fatty Acids blood, Inflammation metabolism
- Abstract
Rheumatoid arthritis (RA) and periodontitis are chronic inflammatory diseases with several pathogenic pathways in common. Evidence supports an association between the diseases, but the exact underlying mechanisms behind the connection are still under investigation. Lipid, fatty acid (FA) and metabolic profile alterations have been associated with several chronic inflammatory diseases, including RA and periodontitis. Mitochondria have a central role in regulating cellular bioenergetic and whole-body metabolic homeostasis, and mitochondrial dysfunction has been proposed as a possible link between the two disorders. The aim of this cross-sectional study was to explore whole-blood FA, serum lipid composition, and carnitine- and choline derivatives in 78 RA outpatients with different degrees of periodontal inflammation. The main findings were alterations in lipid, FA, and carnitine- and choline derivative profiles. More specifically, higher total FA and total cholesterol concentrations were found in active RA. Elevated phospholipid concentrations with concomitant lower choline, elevated medium-chain acylcarnitines (MC-AC), and decreased ratios of MC-AC and long-chain (LC)-AC were associated with prednisolone medication. This may indicate an altered mitochondrial function in relation to the increased inflammatory status in RA disease. Our findings may support the need for interdisciplinary collaboration within the field of medicine and dentistry in patient stratification to improve personalized treatment. Longitudinal studies should be conducted to further assess the potential impact of mitochondrial dysfunction on RA and periodontitis.
- Published
- 2021
- Full Text
- View/download PDF
30. Temporomandibular joint pain and associated magnetic resonance findings: a retrospective study with a control group.
- Author
-
Eriksen ES, Hellem S, Skartveit L, Brun JG, Bøe OE, Moen K, and Geitung JT
- Abstract
Background: To better understand and evaluate clinical usefulness of magnetic resonance imaging (MRI) in diagnosis and treatment of temporomandibular disorders (TMD), parameters for the evaluation are useful., Purpose: To assess a clinically suitable staging system for evaluation of MRI of the temporomandibular joint (TMJ) and correlate the findings with age and some clinical symptoms of the TMJ., Material and Methods: Retrospective analysis of 79 consecutive patients with clinical temporomandibular disorder or diagnosed inflammatory arthritis. Twenty-six healthy volunteers were included as controls. Existing data included TMJ pain, limited mouth opening (<30 mm) and corresponding MRI evaluations of the TMJs., Results: The patients with clinical TMD complaints had statistically significantly more anterior disc displacement (ADD), disc deformation, caput flattening, surface destructions, osteophytes, and caput edema diagnosed by MRI compared to the controls. Among the arthritis patients, ADD, effusion, caput flattening, surface destructions, osteophytes, and caput edema were significantly more prevalent compared to the healthy volunteers. In the control group, disc deformation and presence of osteophytes significantly increased with age, and a borderline significance was found for ADD and surface destructions on the condylar head. No statistically significant associations were found between investigated clinical and MRI parameters., Conclusion: This study presents a clinically suitable staging system for comparable MRI findings in the TMJs. Our results indicate that some findings are due to age-related degenerative changes rather than pathological changes. Results also show that clinical findings such as pain and limited mouth opening may not be related to changes diagnosed by MRI., (© The Foundation Acta Radiologica 2020.)
- Published
- 2020
- Full Text
- View/download PDF
31. Acinar adipose tissue infiltration in salivary gland biopsy is associated with kynurenines-Interferon-γ pathway inflammation biomarkers.
- Author
-
Sardenberg WM, Santos MCLFS, Skarstein K, Carvalho Caser L, Brun JG, Ulvik A, Ueland PM, Mydel PM, Jonsson R, and Valim V
- Subjects
- Adipose Tissue, Biomarkers, Biopsy, Cross-Sectional Studies, Female, Humans, Inflammation, Male, Interferon-gamma, Kynurenine
- Abstract
Objectives: Assess if kynurenines metabolites are biomarkers of damage at labial salivary gland biopsy (LSGB)., Methods: This is a cross-sectional study including 99 patients with primary Sjögren's syndrome (AECG 2002 or ACR/EULAR 2017). Kynurenines were measured in plasma using liquid chromatography-tandem mass spectrometry., Results: 95.9% were females, 51±12 years. Most had focal lymphocytic sialadenitis with focus score ≥1 (73.7%, n=73/99). The majority had mild to severe acinar atrophy (70.4%, n=57/81) and adipose infiltration (51.2%, n=39/80). Individuals with adipose infiltration were older (53.49±12.33 vs. 47.51±11.29 years, p=0.016), showed higher frequency of glandular dysfunction and higher kynurenines levels. Schirmer's test ≤ 5 mm/5min was found in 69.2% of individuals with adipose infiltration compared to 41% without (p=0.012) and unstimulated whole salivary flow (UWSF) was found in 87.2% compared to 70% without adipose infiltration (p=0.063). Additionally, individuals with adipose infiltration showed higher kynurenines metabolites compared with those without: quinolinic acid (503.35±193.30 vs. 427.35±285.76 nmol/L, p=0.029), kynurenine (1.99±0.6, 54 vs. 1.61±0.46 μmol/L, p=0.006), kynurenine/tryptophan ratio (KTR) (0.030±0.09 vs. 0.025±0.01, p=0.031) and anthranilic acid (03±4.96 vs. 16.46±5.24 nmol/L, p=0.022)., Conclusions: Kynurenines are biomarkers of greater adipose infiltration in LSGB and glandular dysfunction suggesting that activation of interferon-γ pathway is involved in the salivary and lacrimal glands damage.
- Published
- 2020
32. Juvenile Sjögren's Syndrome: Clinical Characteristics With Focus on Salivary Gland Ultrasonography.
- Author
-
Hammenfors DS, Valim V, Bica BERG, Pasoto SG, Lilleby V, Nieto-González JC, Silva CA, Mossel E, Pereira RMR, Coelho A, Bootsma H, Thatayatikom A, Brun JG, and Jonsson MV
- Subjects
- Adolescent, Child, Child, Preschool, Cross-Sectional Studies, Female, Humans, Infant, Male, Severity of Illness Index, Salivary Glands diagnostic imaging, Sjogren's Syndrome diagnosis, Ultrasonography methods
- Abstract
Objective: Juvenile Sjögren's syndrome (SS) is a rare, poorly defined, and possibly underdiagnosed condition affecting children and adolescents. The aim of this study was to characterize symptoms and clinical findings of juvenile SS and to explore the clinical application of major salivary gland ultrasonography (SGUS) in patients with juvenile SS., Methods: A cross-sectional multicenter study recruited patients with disease onset until age 18 years (n = 67). Disease characteristics were recorded, and unstimulated whole sialometry and SGUS examination of the parotid and submandibular salivary glands were performed., Results: The female:male ratio was 58:9. The mean age at first symptom was 10.2 years and 12.1 years at diagnosis. Ocular and oral symptoms were noted in 42 of 67 patients (63%) and 53 of 66 patients (80%), respectively. The American-European Consensus Group or American College of Rheumatology/European League Against Rheumatism classification criteria for primary SS were fulfilled by 42 of 67 patients (63%). Pathologic SGUS findings were observed in 41 of 67 patients (61%); 26 of 41 SGUS+ patients (63%) fulfilled primary SS criteria. Salivary gland enlargements/parotitis were noted in 37 of 58 patients and were nonsignificantly associated with SGUS+ status (P = 0.066). The mean levels of saliva were 5.6 ml/15 minutes in SGUS- patients compared to 3.3 ml/15 minutes in the SGUS+ patients (P = 0.049). A total of 36 of 41 SGUS+ patients (88%) were anti-Ro/La+ compared to 14 of 26 SGUS- patients (54%) (P = 0.001). In addition, 24 of 39 SGUS+ patients (62%) were positive for rheumatoid factor (RF), whereas only 5 of 25 SGUS- patients (20%) were RF+ (P = 0.001)., Conclusion: Juvenile SS is characterized by a large spectrum of clinical symptoms and findings. Several glandular and extraglandular parameters such as hyposalivation, swollen salivary glands, and autoantibodies are associated with pathologic SGUS findings., (© 2019 The Authors. Arthritis Care & Research published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology.)
- Published
- 2020
- Full Text
- View/download PDF
33. Assessment of major salivary gland ultrasonography in Sjögren's syndrome. A comparison between bedside and post-examination evaluations.
- Author
-
Hammenfors DS, Causevic H, Assmus J, Brun JG, Jonsson R, and Jonsson MV
- Subjects
- Humans, Parotid Gland, Reproducibility of Results, Submandibular Gland, Salivary Glands diagnostic imaging, Sjogren's Syndrome diagnostic imaging, Ultrasonography methods
- Abstract
Objectives: Major salivary gland ultrasonography (SGUS) is a suitable diagnostic tool in Sjögren's syndrome (SS). We aimed to determine the more representative gland, projection and format most applicable for reproducible image analysis., Methods: One investigator performed SGUS in patients with SS. Parotid and submandibular glands were examined in longitudinal and transverse planes and evaluated bedside using a simplified scoring system (0-3). Longitudinal and transverse images and videos of all glands were stored and later evaluated/graded by three investigators, at two time-points. Agreement was calculated using intraclass correlation coefficient (ICC)., Results: The ICC for static image and video scoring compared to bedside evaluation ranged from 0.131 to 0.882. Average ICC for longitudinal/transverse image was 0.667/0.662, and 0.683/0.510 for longitudinal/transverse video. Interobserver reliability was good to excellent (0.81-0.94). Intraobserver reliability scores ranged from fair to excellent (0.46-0.96). The correlation between image and video evaluations of all modalities and examiners was good to excellent (0.614-0.904). The best mean ICC was found for the longitudinal projection of the left parotid gland (0.861) and the lowest mean ICC was for the transverse projection of the left submandibular gland (0.66)., Conclusions: Our study indicates a trend favouring longitudinal video of the parotid gland as preferred projection, gland and storage format.
- Published
- 2019
34. Single Cell Based Phosphorylation Profiling Identifies Alterations in Toll-Like Receptor 7 and 9 Signaling in Patients With Primary Sjögren's Syndrome.
- Author
-
Davies R, Sarkar I, Hammenfors D, Bergum B, Vogelsang P, Solberg SM, Gavasso S, Brun JG, Jonsson R, and Appel S
- Subjects
- Adult, Aged, Case-Control Studies, Cytokines metabolism, Female, Humans, Killer Cells, Natural metabolism, Male, Middle Aged, T-Lymphocytes metabolism, Phosphorylation physiology, Signal Transduction physiology, Sjogren's Syndrome metabolism, Toll-Like Receptor 7 metabolism, Toll-Like Receptor 9 metabolism
- Abstract
Primary Sjögren's syndrome (pSS) is associated with polymorphisms and mRNA expression profiles that are indicative of an exaggerated innate and type I IFN immune response. Excessive activation potential of signaling pathways may play a role in this profile, but the intracellular signaling profile of the disease is not well characterized. To gain insights into potentially dysfunctional intracellular signaling profiles of pSS patients we conducted an exploratory analysis of MAPK/ERK and JAK/STAT signaling networks in peripheral blood mononuclear cells (PBMC) from 25 female pSS patients and 25 female age-matched healthy donors using phospho-specific flow cytometry. We analyzed unstimulated samples, as well as samples during a 4 h time period following activation of Toll-like receptor (TLR) 7 and 9. Expression levels of MxA, IFI44, OAS1, GBP1 , and GBP2 in PBMC were analyzed by real-time PCR. Cytokine levels in plasma were determined using a 25-plex Luminex-assay. Principal component analysis (PCA) showed that basal phosphorylation profiles could be used to differentiate pSS patients from healthy donor samples by stronger intracellular signaling pathway activation in NK and T cells relative to B cells. Stimulation of PBMC with TLR7 and -9 ligands showed significant differences in the phosphorylation profiles between samples from pSS patients and healthy donors. Including clinical parameters such as extraglandular manifestations (EGM), we observed stronger responses of NF-κB and STAT3 S727 in B cells from EGM-negative patients compared to EGM-positive patients and healthy controls. Plasma cytokine levels were correlated to the basal phosphorylation levels in these patients. In addition, 70% of the patients had a positive IFN score. These patients differed from the IFN score negative patients regarding their phosphorylation profiles and their plasma cytokine levels. In conclusion, we here report increased signaling potentials in peripheral B cells of pSS patients in response to TLR7 and -9 stimulation through STAT3 S727 and NF-κB that correlate with a type I IFN signature. Induction of these pathways could contribute to the generation of a type I IFN signature in pSS. Patients displaying elevated potentiation of STAT3 S727 and NF-κB signaling could therefore benefit from therapies targeting these pathways.
- Published
- 2019
- Full Text
- View/download PDF
35. Marine ω-3, vitamin D levels, disease outcome and periodontal status in rheumatoid arthritis outpatients.
- Author
-
Beyer K, Lie SA, Kjellevold M, Dahl L, Brun JG, and Bolstad AI
- Subjects
- Aged, Arthritis, Rheumatoid complications, Diet adverse effects, Diet statistics & numerical data, Diet Surveys, Dietary Supplements analysis, Fatty Acids, Omega-3 analysis, Female, Humans, Male, Middle Aged, Nutritional Status, Outpatients, Periodontitis etiology, Prevalence, Vitamin D analysis, Arthritis, Rheumatoid blood, Fatty Acids, Omega-3 blood, Periodontitis epidemiology, Seafood analysis, Vitamin D blood
- Abstract
Objectives: Marine ω-3 fatty acids (FAs) and Vitamin D (VitD) are reportedly capable of down-regulating inflammation in rheumatoid arthritis (RA) and periodontal disease. This study was undertaken to relate marine FA and VitD status to RA disease status and periodontal conditions., Methods: RA outpatients (age ≥35 y) were consecutively recruited. Rheumatologic clinical data were collected and periodontal status obtained. A food frequency questionnaire was used to estimate fish and supplement intake. FA profiles in whole-blood and serum VitD levels were determined., Results: A total of 78 RA patients (age 57 ± 12 y, disease duration 15 ± 11 y) were included, 58% had active RA. Periodontitis was diagnosed in 82% of the patients, 18% had severe periodontitis. Seropositivity for rheumatoid factor and/or anticitrullinated protein antibodies was related to higher prevalence of periodontitis (P= 0.008). Seafood intake in accordance with nutritional recommendations was associated with better RA disease outcome (largest P= 0.008). An ω-3 index >8, present in 14% of the patients, correlated with a more desirable patient global health assessment scored on a visual analog scale (VAS; P= 0.004), lower periodontal probing depth (PD; P= 0.021), and ω-3 supplementation (P= 0.001). Serum VitD levels >50 nmol/L were found in 89%, of these 48% had VitD levels ≥75 nmol/L, no differences were found for RA disease activity and periodontal measurements., Conclusions: Seropositive RA patients had a higher prevalence of periodontitis than seronegative patients. An ω-3 index >8 was related to ω-3 supplementation and more desirable VAS and lower PD. VitD status was satisfactory for most patients and was not associated with differences in RA severity or periodontal diagnosis., (Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
36. Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health.
- Author
-
Beyer K, Zaura E, Brandt BW, Buijs MJ, Brun JG, Crielaard W, and Bolstad AI
- Subjects
- Aged, Anti-Inflammatory Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Cross-Sectional Studies, DNA, Bacterial analysis, DNA, Bacterial classification, DNA, Bacterial genetics, Female, Gingiva drug effects, Humans, Male, Microbiota drug effects, Middle Aged, Periodontitis complications, Periodontitis drug therapy, Porphyromonas gingivalis genetics, Prednisolone therapeutic use, RNA, Ribosomal, 16S genetics, Sequence Analysis, DNA, Arthritis, Rheumatoid complications, Gingiva microbiology, Microbiota genetics, Periodontitis microbiology
- Abstract
Objective: Rheumatoid arthritis (RA) and periodontitis are chronic inflammatory diseases that share common risk factors. However, the bidirectional relationship between RA and periodontal disease is not fully understood. This study was undertaken to describe the bacterial component of the subgingival microbiome in RA patients and to relate this to RA disease activity and periodontal status., Methods: Patients with chronic established RA (N = 78) were periodontally examined and their subgingival plaque samples were collected; their clinical and laboratory data on RA status and medication were obtained from medical records. Bacterial DNA was quantified by universal 16S rDNA qPCR, and Porphyromonas gingivalis by species-specific qPCR. For microbiome assessment, 16S rDNA amplicon sequencing was performed., Results: Active RA was diagnosed in 58% of the patients and periodontitis in 82% (mild: 9%, moderate: 55%, severe: 18%). P. gingivalis was present in 14% of the samples. Different levels of gingival bleeding, periodontal probing depth, RA disease status, prednisolone use and smoking were associated with significantly different microbiome compositions. Two subgingival microbial community types were discerned., Conclusion: In RA patients with active disease, anti-inflammatory medication as part of RA therapy was associated with better oral health status and a healthier subgingival microbiome compared to that of RA patients in remission, especially those in remission who were current smokers. RA patients in remission with current smoking status may particularly benefit from a systematic periodontal treatment program. The potential role of microbial community types in patient stratification and personalized therapy should be assessed in longitudinal studies., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2018
- Full Text
- View/download PDF
37. T follicular-like helper cells in the peripheral blood of patients with primary Sjögren's syndrome.
- Author
-
Brokstad KA, Fredriksen M, Zhou F, Bergum B, Brun JG, Cox RJ, and Skarstein K
- Abstract
Primary Sjögren's syndrome (pSS) is a chronic autoimmune disease characterized by exocrine gland dysfunction, mainly causing sicca symptoms. B cells have a prominent role in SS, and the T follicular helper (T
FH ) cells provide B cells with survival and specialization signals in germinal centres. Here, we investigate peripheral TFH cells in pSS. Sixteen pSS patients and healthy controls were enrolled in the study, with 13 women and 3 men in each group. Whole blood was collected and separated into PBMC and plasma, followed by cryopreservation. Plasma samples were analysed for Ro52, Ro60 and La48 autoantibodies by indirect ELISA. For flow cytometric analysis, we defined 4 subsets of TFH-like cells within the CD3+ CD4+ CXCR5+ population, namely the ICOS- PD-1- , ICOS- PD-1+ , ICOS+ PD-1- and ICOS+ PD-1+ ("TFH") cells. We also investigated 4 CD19+ B cell subsets, the CD20+ CD27+ CD38- memory B cells, CD20+ CD27+ CD38+ memory B cells, CD20- CD27+ CD38++ CD138- plasmablasts and CD20- CD27+ CD38++ CD138+ plasma cells. We observed higher fractions of ICOS+ PD-1- cells, ICOS+ PD-1+ ("TFH ") cells and plasmablasts in pSS patients compared to controls, and lower frequencies of both types of memory B cells. The number of TFH cells correlated positively with the levels of plasmablasts and plasma cells in the pSS patients, but not in the controls. The pSS patients were stratified according to Ro52/Ro60/La48 serology, and a positive association was found between autoantibody levels and increased level of TFH cells, plasmablasts and plasma cells and lowered levels of memory B cells. We observed a higher response to Ro/La stimulation in pSS patients compared to controls of the memory B cells, although only significantly for the CD38- memory B cells. Overall, a pathological relation between the ICOS+ T follicular-like helper cells and B cells in pSS was observed, but further work should be conducted to explore their overall impact upon disease progression., (© 2018 The Foundation for the Scandinavian Journal of Immunology.)- Published
- 2018
- Full Text
- View/download PDF
38. Aberrant cell signalling in PBMCs upon IFN-α stimulation in primary Sjögren's syndrome patients associates with type I interferon signature.
- Author
-
Davies R, Hammenfors D, Bergum B, Vogelsang P, Gavasso S, Brun JG, Jonsson R, and Appel S
- Subjects
- Adult, Aged, Autoantibodies blood, Cells, Cultured, Female, Humans, Immunization, Interferon-alpha immunology, Male, Mutation genetics, Phosphorylation, STAT1 Transcription Factor genetics, STAT3 Transcription Factor genetics, Signal Transduction, Sjogren's Syndrome immunology, Transcriptome, B-Lymphocytes immunology, Immunotherapy methods, Leukocytes, Mononuclear immunology, STAT1 Transcription Factor metabolism, STAT3 Transcription Factor metabolism, T-Lymphocytes immunology
- Abstract
Primary Sjögren's syndrome (pSS) is a complex systemic autoimmune disease with heterogeneous disease manifestations. Genetic predisposition, hormonal and environmental factors are all thought to contribute to disease etiology and pathogenesis. A better understanding of the disease pathogenesis is required in order to establish new targeted therapies. We analysed MAPK/ERK and JAK/STAT signalling networks in peripheral blood mononuclear cells (PBMCs) upon stimulation with interferon alpha 2b (IFN-α2b) by flow cytometry to define potentially dysfunctional intracellular signalling pathways involved in disease pathogenesis. Cells derived from pSS patients displayed small but significant increases in basal phosphorylation levels of numerous signalling proteins compared to cells from healthy donors. The phosphorylation profiles following stimulation with IFNα2b differed significantly between pSS patients and healthy donors, especially regarding STAT1 Y701. PCA further grouped patients according to clinical characteristics. Type I IFN induced gene expression was found to negatively correlate with the IFN-α2b induced phosphorylation of STAT3 S727 in T cells and positively with pSTAT1 Y701 in B cells. Increases in pSTAT1 Y701 were associated with the presence of autoantibodies. Our results indicate involvement of both STAT3 S727 and STAT1 Y701 pathways in pSS patients. Therapies targeting these pathways might therefore be beneficial for certain subgroups of patients., (© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2018
- Full Text
- View/download PDF
39. Patients with Primary Sjögren's Syndrome Have Alterations in Absolute Quantities of Specific Peripheral Leucocyte Populations.
- Author
-
Davies R, Hammenfors D, Bergum B, Jakobsen K, Solheim M, Vogelsang P, Brun JG, Bryceson Y, Jonsson R, and Appel S
- Subjects
- Aged, Antibodies, Antinuclear blood, Antigens, CD metabolism, Blood Circulation, Cluster Analysis, Disease Progression, Female, Flow Cytometry, Humans, Male, Middle Aged, Sjogren's Syndrome pathology, Granulocytes immunology, Lymphocytes immunology, Monocytes immunology, Sjogren's Syndrome immunology
- Abstract
An accurate dissection of peripheral blood enumeration is lacking in primary Sjögren's syndrome (pSS). The purpose of this study was to quantify different leucocyte populations in peripheral blood of patients with pSS. Numbers of specific leucocyte subsets were determined in 86 pSS patients and 74 healthy donors quantifying 21 distinct subtypes by flow cytometry. Subgroups of pSS patients were stratified based on presence of extraglandular manifestations (EGMs) and SSA/SSB autoantibodies. Overall, pSS patients manifested decreased lymphocyte subpopulations compared to healthy donors. Such decreases were more pronounced in SSA/SSB positive patients and patients with EGM. Granulocyte and monocyte subpopulations were increased in pSS patients compared to healthy donors, with the greatest increases in SSA/SSB positive patients. Unsupervised hierarchal clustering based on cell quantities was used to further subgroup the pSS patients into four clusters. One of the clusters characterized by higher concentrations of NKT cells, CD56hi NK cells, CD20
+ CD38- B cells and CD8+ CD38- T cells was associated with weaker clinical symptoms than the other clusters, possibly marking a milder disease phenotype. In conclusion, our analyses indicate significant alterations in the cellular profiles of peripheral blood leucocytes in patients with pSS and may help to stratify the patients according to disease severity., (© 2017 The Foundation for the Scandinavian Journal of Immunology.)- Published
- 2017
- Full Text
- View/download PDF
40. Long-term follow-up in primary Sjögren's syndrome reveals differences in clinical presentation between female and male patients.
- Author
-
Ramírez Sepúlveda JI, Kvarnström M, Eriksson P, Mandl T, Norheim KB, Johnsen SJ, Hammenfors D, Jonsson MV, Skarstein K, Brun JG, Rönnblom L, Forsblad-d'Elia H, Magnusson Bucher S, Baecklund E, Theander E, Omdal R, Jonsson R, Nordmark G, and Wahren-Herlenius M
- Subjects
- Autoantibodies metabolism, Biomarkers blood, Comorbidity, Female, Follow-Up Studies, Humans, Male, Middle Aged, Severity of Illness Index, Sjogren's Syndrome complications, Sjogren's Syndrome diagnosis, Sjogren's Syndrome physiopathology
- Abstract
Background: Despite men being less prone to develop autoimmune diseases, male sex has been associated with a more severe disease course in several systemic autoimmune diseases. In the present study, we aimed to investigate differences in the clinical presentation of primary Sjögren's syndrome (pSS) between the sexes and establish whether male sex is associated with a more severe form of long-term pSS., Methods: Our study population included 967 patients with pSS (899 females and 68 males) from Scandinavian clinical centers. The mean follow-up time (years) was 8.8 ± 7.6 for women and 8.5 ± 6.2 for men (ns). Clinical data including serological and hematological parameters and glandular and extraglandular manifestations were compared between men and women., Results: Male patient serology was characterized by more frequent positivity for anti-Ro/SSA and anti-La/SSB (p = 0.02), and ANA (p = 0.02). Further, men with pSS were more frequently diagnosed with interstitial lung disease (p = 0.008), lymphadenopathy (p = 0.04) and lymphoma (p = 0.007). Conversely, concomitant hypothyroidism was more common among female patients (p = 0.009)., Conclusions: We observe enhanced serological responses and higher frequencies of lymphoma-related extraglandular manifestations in men with pSS. Notably, lymphoma itself was also significantly more common in men. These observations may reflect an aggravated immune activation and a more severe pathophysiological state in male patients with pSS and indicate a personalized managing of the disease due to the influence of the sex of patients with pSS.
- Published
- 2017
- Full Text
- View/download PDF
41. Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons.
- Author
-
Li H, Reksten TR, Ice JA, Kelly JA, Adrianto I, Rasmussen A, Wang S, He B, Grundahl KM, Glenn SB, Miceli-Richard C, Bowman S, Lester S, Eriksson P, Eloranta ML, Brun JG, Gøransson LG, Harboe E, Guthridge JM, Kaufman KM, Kvarnström M, Cunninghame Graham DS, Patel K, Adler AJ, Farris AD, Brennan MT, Chodosh J, Gopalakrishnan R, Weisman MH, Venuturupalli S, Wallace DJ, Hefner KS, Houston GD, Huang AJW, Hughes PJ, Lewis DM, Radfar L, Vista ES, Edgar CE, Rohrer MD, Stone DU, Vyse TJ, Harley JB, Gaffney PM, James JA, Turner S, Alevizos I, Anaya JM, Rhodus NL, Segal BM, Montgomery CG, Scofield RH, Kovats S, Mariette X, Rönnblom L, Witte T, Rischmueller M, Wahren-Herlenius M, Omdal R, Jonsson R, Ng WF, Nordmark G, Lessard CJ, and Sivils KL
- Subjects
- 2',5'-Oligoadenylate Synthetase biosynthesis, Alleles, Alternative Splicing genetics, Female, Gene Expression Regulation, Genetic Association Studies, Genetic Predisposition to Disease, Humans, Interferon Type I metabolism, Male, Sjogren's Syndrome metabolism, Sjogren's Syndrome pathology, Virus Diseases genetics, Virus Diseases virology, 2',5'-Oligoadenylate Synthetase genetics, Interferon Type I genetics, Quantitative Trait Loci genetics, Sjogren's Syndrome genetics
- Abstract
Sjögren's syndrome (SS) is a common, autoimmune exocrinopathy distinguished by keratoconjunctivitis sicca and xerostomia. Patients frequently develop serious complications including lymphoma, pulmonary dysfunction, neuropathy, vasculitis, and debilitating fatigue. Dysregulation of type I interferon (IFN) pathway is a prominent feature of SS and is correlated with increased autoantibody titers and disease severity. To identify genetic determinants of IFN pathway dysregulation in SS, we performed cis-expression quantitative trait locus (eQTL) analyses focusing on differentially expressed type I IFN-inducible transcripts identified through a transcriptome profiling study. Multiple cis-eQTLs were associated with transcript levels of 2'-5'-oligoadenylate synthetase 1 (OAS1) peaking at rs10774671 (PeQTL = 6.05 × 10-14). Association of rs10774671 with SS susceptibility was identified and confirmed through meta-analysis of two independent cohorts (Pmeta = 2.59 × 10-9; odds ratio = 0.75; 95% confidence interval = 0.66-0.86). The risk allele of rs10774671 shifts splicing of OAS1 from production of the p46 isoform to multiple alternative transcripts, including p42, p48, and p44. We found that the isoforms were differentially expressed within each genotype in controls and patients with and without autoantibodies. Furthermore, our results showed that the three alternatively spliced isoforms lacked translational response to type I IFN stimulation. The p48 and p44 isoforms also had impaired protein expression governed by the 3' end of the transcripts. The SS risk allele of rs10774671 has been shown by others to be associated with reduced OAS1 enzymatic activity and ability to clear viral infections, as well as reduced responsiveness to IFN treatment. Our results establish OAS1 as a risk locus for SS and support a potential role for defective viral clearance due to altered IFN response as a genetic pathophysiological basis of this complex autoimmune disease.
- Published
- 2017
- Full Text
- View/download PDF
42. Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium.
- Author
-
Brito-Zerón P, Acar-Denizli N, Zeher M, Rasmussen A, Seror R, Theander E, Li X, Baldini C, Gottenberg JE, Danda D, Quartuccio L, Priori R, Hernandez-Molina G, Kruize AA, Valim V, Kvarnstrom M, Sene D, Gerli R, Praprotnik S, Isenberg D, Solans R, Rischmueller M, Kwok SK, Nordmark G, Suzuki Y, Giacomelli R, Devauchelle-Pensec V, Bombardieri M, Hofauer B, Bootsma H, Brun JG, Fraile G, Carsons SE, Gheita TA, Morel J, Vollenveider C, Atzeni F, Retamozo S, Horvath IF, Sivils K, Mandl T, Sandhya P, De Vita S, Sanchez-Guerrero J, van der Heijden E, Trevisani VFM, Wahren-Herlenius M, Mariette X, and Ramos-Casals M
- Subjects
- Adult, Aged, Antibodies, Antinuclear blood, Cross-Sectional Studies, Eye Diseases etiology, Female, Humans, Male, Middle Aged, Phenotype, Prevalence, Sjogren's Syndrome blood, Sjogren's Syndrome complications, Sjogren's Syndrome diagnosis, Spatial Analysis, Black or African American statistics & numerical data, Asian People statistics & numerical data, Hispanic or Latino statistics & numerical data, Registries, Sjogren's Syndrome ethnology, White People statistics & numerical data
- Abstract
Objectives: To analyse the influence of geolocation and ethnicity on the clinical presentation of primary Sjögren's syndrome (SjS) at diagnosis., Methods: The Big Data Sjögren Project Consortium is an international, multicentre registry designed in 2014. By January 2016, 20 centres from five continents were participating. Multivariable logistic regression analyses were performed., Results: We included 7748 women (93%) and 562 men (7%), with a mean age at diagnosis of primary SjS of 53 years. Ethnicity data were available for 7884 patients (95%): 6174 patients (78%) were white, 1066 patients (14%) were Asian, 393 patients (5%) were Hispanic, 104 patients (1%) were black/African-American and 147 patients (2%) were of other ethnicities. SjS was diagnosed a mean of 7 years earlier in black/African-American compared with white patients; the female-to-male ratio was highest in Asian patients (27:1) and lowest in black/African-American patients (7:1); the prevalence of sicca symptoms was lowest in Asian patients; a higher frequency of positive salivary biopsy was found in Hispanic and white patients. A north-south gradient was found with respect to a lower frequency of ocular involvement in northern countries for dry eyes and abnormal ocular tests in Europe (OR 0.46 and 0.44, respectively) and Asia (OR 0.18 and 0.49, respectively) compared with southern countries. Higher frequencies of antinuclear antibodies (ANAs) were reported in northern countries in America (OR=1.48) and Asia (OR=3.80) while, in Europe, northern countries had lowest frequencies of ANAs (OR=0.67) and Ro/La (OR=0.69)., Conclusions: This study provides the first evidence of a strong influence of geolocation and ethnicity on the phenotype of primary SjS at diagnosis., Competing Interests: Competing interests: None declared., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.)
- Published
- 2017
- Full Text
- View/download PDF
43. Serum calprotectin is a biomarker of carotid atherosclerosis in patients with primary Sjögren's syndrome.
- Author
-
Balarini GM, Zandonade E, Tanure L, Ferreira GA, Sardenberg WM, Serrano ÉV, Dias CC, Navarro TP, Nordal HH, Mydel PM, Brun JG, Brokstad KA, Gerdts E, Jonsson R, and Valim V
- Subjects
- Adult, Atherosclerosis blood, Atherosclerosis complications, Biomarkers blood, Carotid Artery Diseases blood, Carotid Artery Diseases complications, Chemokine CCL2 blood, Female, Hepatocyte Growth Factor blood, Humans, Male, Middle Aged, Receptors, Tumor Necrosis Factor, Type II blood, Severity of Illness Index, Sjogren's Syndrome blood, Atherosclerosis diagnosis, Carotid Artery Diseases diagnosis, Leukocyte L1 Antigen Complex blood, Sjogren's Syndrome complications
- Abstract
Objectives: We aimed to identify the association of carotid atherosclerosis with the traditional risk factors, disease features, cytokine profile, and calprotectin in patients with primary Sjögren's syndrome (pSS)., Methods: 63 primary pSS patients and 63 age- and sex-matched healthy controls underwent carotid ultrasound, clinical and laboratory examination. The presence of carotid plaques was taken as carotid atherosclerosis. The covariates of carotid atherosclerosis were identified in univariate and multivariate regressions., Results: Patients with pSS had higher prevalence of carotid atherosclerosis (13% vs. 2%, p<0.05) and higher serum levels of calprotectin, tumour necrosis factor receptor 2 (TNF-R2), hepatocyte growth factor (HGF), and monocyte chemoattractant protein-1 (MCP-1) than controls. Sex, menopause, and the prevalence of traditional cardiovascular did not differ between groups (all p>0.05). In univariate analyses, serum calprotectin, most traditional cardiovascular (age, male sex, metabolic syndrome, hypertension, hypertriglyceridaemia, and serum creatinine), and some disease-associated risk factors (glucocorticoid or saliva substitute use, constitutional domain of Eular-Sjögren's syndrome disease activity index - EULAR) were associated with a higher risk for plaque. In a multivariate analysis, having pSS and higher serum calprotectin were associated with carotid atherosclerosis independent of traditional risk factors., Conclusions: pSS have a higher prevalence of carotid atherosclerosis, which is associated with higher serum calprotectin level independent of traditional cardiovascular risk factors. Our findings suggest calprotectin as a biomarker of subclinical atherosclerosis in pSS.
- Published
- 2016
44. Sjögren's syndrome patients with ectopic germinal centers present with a distinct salivary proteome.
- Author
-
Delaleu N, Mydel P, Brun JG, Jonsson MV, Alimonti A, and Jonsson R
- Subjects
- Adult, Aged, Biomarkers analysis, Female, Gene Ontology, Humans, Male, Middle Aged, Sialadenitis etiology, Sialadenitis metabolism, Sjogren's Syndrome complications, Sjogren's Syndrome genetics, Xerostomia etiology, Xerostomia metabolism, Germinal Center metabolism, Phenotype, Proteome analysis, Saliva metabolism, Sjogren's Syndrome metabolism
- Abstract
Objective: Clinical expression of SS shows considerable interpatient heterogeneity. Thus, the aim of this study was to assess whether individual salivary proteomic profiles provide a framework for identification of disease-phenotype-driven biomarker signatures., Methods: Using a 187-plex capture antibody-based assay, proteomic biomarker profiles from unstimulated whole saliva were generated from a SS-cohort representing six clinically distinct disease phenotypes. Discriminant function analyses identified the most powerful biomarker signatures for correct recapitulation of each patient's status with respect to hyposalivation and histopathological features of salivary gland inflammation. In addition, gene ontology-based network analyses allowed systematic interpretation of the molecular patterns underlying these specific disease features., Results: Presentation of hyposalivation was associated with significant alteration in 22 out of 119 reliably detectable biomarkers. Thereof, a 4-plex signature allowed accurate prediction of salivary gland function for >80% of the cases. With respect to histopathological features, the most distinct profiles were identified in conjunction with ectopic germinal centres. Selected from the 13 analytes relevant here, pregnancy-associated plasma protein A, thrombospondin 1 and peptide YY would recapitulate the presence or absence of tertiary lymphoid organization for 93.8% of the patients. Whereas functional annotation of alterations associated with hyposalivation identified the IL1 system as a dominant pro-inflammatory component, changes observed in context with ectopic lymphoid organization revealed specific shifts in chemotactic profiles and altered regulation of apoptotic processes., Conclusion: Multivariate analyses of a patient's salivary proteome could reliably recapitulate specific aspects of SS disease. Accessible and repetitively collectable, such biomarker signatures harbour great potential for patient subclassification and subsequent follow-up., (© The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
45. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
- Author
-
Seror R, Bootsma H, Saraux A, Bowman SJ, Theander E, Brun JG, Baron G, Le Guern V, Devauchelle-Pensec V, Ramos-Casals M, Valim V, Dörner T, Tzioufas A, Gottenberg JE, Solans Laqué R, Mandl T, Hachulla E, Sivils KL, Ng WF, Fauchais AL, Bombardieri S, Priori R, Bartoloni E, Goeb V, Praprotnik S, Sumida T, Nishiyama S, Caporali R, Kruize AA, Vollenweider C, Ravaud P, Meiners P, Brito-Zerón P, Vitali C, and Mariette X
- Subjects
- Aged, Diagnostic Self Evaluation, Disease Progression, Female, Humans, Male, Middle Aged, Patient Satisfaction, Prospective Studies, ROC Curve, Sjogren's Syndrome psychology, Symptom Assessment psychology, Health Status, Severity of Illness Index, Sjogren's Syndrome diagnosis, Symptom Assessment methods
- Abstract
Objectives: To define disease activity levels, minimal clinically important improvement (MCII) and patient-acceptable symptom state (PASS) with the primary Sjögren's syndrome (SS) disease activity indexes: European League Against Rheumatism (EULAR) SS disease activity index (ESSDAI) and EULAR SS patient-reported index (ESSPRI)., Methods: For 790 patients from two large prospective cohorts, ESSDAI, physician evaluation of disease activity, ESSPRI and patients' satisfaction with their current health status were recorded. Receiver operating characteristic curve analyses and anchoring methods were used to estimate disease activity levels of ESSDAI and the PASS of ESSPRI. At follow-up visit, patients and physicians assessed, respectively, whether symptoms and disease activity have improved or not. An anchoring method based on this evaluation was used to estimate MCII of ESSDAI and ESSPRI., Results: Low-activity (ESSDAI<5), moderate-activity (5≤ESSDAI≤13) and high-activity (ESSDAI≥14) levels were defined. MCII of ESSDAI was defined as an improvement of at least three points. The PASS estimate was defined as an ESSPRI<5 points and MCII as a decrease of at least one point or 15%., Conclusions: This study determined disease activity levels, PASS and MCII of ESSDAI and ESSPRI. These results will help designing future clinical trials in SS. For evaluating systemic complications, the proposal is to include patients with moderate activity (ESSDAI≥5) and define response to treatment as an improvement of ESSDAI at least three points. For addressing patient-reported outcomes, inclusion of patients with unsatisfactory symptom state (ESSPRI≥5) and defining response as an improvement of ESSPRI at least one point or 15% seems reasonable., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/)
- Published
- 2016
- Full Text
- View/download PDF
46. Atherosclerosis in Sjögren's syndrome: evidence, possible mechanisms and knowledge gaps.
- Author
-
Valim V, Gerdts E, Jonsson R, Ferreira GA, Brokstad KA, Brun JG, Midtbø H, and Mydel PM
- Subjects
- Animals, Atherosclerosis blood, Atherosclerosis diagnosis, Atherosclerosis immunology, Biomarkers blood, Comorbidity, Humans, Inflammation Mediators blood, Inflammation Mediators immunology, Prognosis, Risk Assessment, Risk Factors, Signal Transduction, Sjogren's Syndrome blood, Sjogren's Syndrome diagnosis, Sjogren's Syndrome immunology, Atherosclerosis epidemiology, Sjogren's Syndrome epidemiology
- Abstract
Inflammation has been associated with higher cardiovascular risk in rheumatic autoimmune diseases like rheumatoid arthritis (RA) and systemic lupus erythematosus. More recently, primary Sjögren's syndrome (pSS) was also demonstrated as an independent risk factor for cardiovascular disease, emerging as a new interesting model to study atherosclerosis in autoimmune diseases. Patients with pSS have a higher prevalence of developing traditional cardiovascular risk factors like hypertension and dyslipidaemia predisposing for endothelial dysfunction and premature atherosclerosis. However, the disease-specific mechanisms for premature atherosclerosis in pSS are not fully understood. The aim of this review was to critically analyse the current literature on cardiovascular risks in pSS and to discuss the traditional and disease-associated risk factors. We also suggest possible new mechanisms that should be explored in future research to close the current knowledge gaps on the association of pSS, premature atherosclerosis, and clinical cardiovascular disease.
- Published
- 2016
47. TLR-7 and -9 Stimulation of Peripheral Blood B Cells Indicate Altered TLR Signalling in Primary Sjögren's Syndrome Patients by Increased Secretion of Cytokines.
- Author
-
Karlsen M, Jonsson R, Brun JG, Appel S, and Hansen T
- Subjects
- Adult, Aged, Cytokines blood, Female, Humans, Lymphocyte Activation immunology, Middle Aged, Young Adult, B-Lymphocytes immunology, Cytokines immunology, Sjogren's Syndrome immunology, Toll-Like Receptor 7 immunology, Toll-Like Receptor 9 immunology
- Abstract
Primary Sjögren's syndrome (pSS) is a chronic, inflammatory autoimmune disease characterised by lymphocytic infiltrations in the exocrine glands, resulting in destruction of salivary and lacrimal glands. B cells have an important role in the disease, as detection of autoantibodies against SSA/Ro or SSB/La is one of the diagnostic criteria, being found in a majority of the patients. Toll-like receptors (TLR) are pattern recognition receptors. TLR-7 and -9 are found in endosomes and bind microbial nucleic acids. We have previously shown that pSS patients and healthy controls have similar expression pattern of TLR-7 and -9 in various B-cell populations. In this study we further analysed the responsiveness of B cells upon TLR stimulation. B cells isolated from peripheral blood of 21 pSS patients and 18 healthy controls were stimulated with TLR-7 and -9 ligands for 24 h before being analysed for the expression of certain surface markers and intracellular cytokine levels by flow cytometry. Secreted cytokines were measured by a multiplex cytokine assay. Patients with pSS had more naïve and less preswitched memory B cells compared to controls in unstimulated as well as via TLR-7 stimulated cells. Unstimulated and via TLR-7 stimulated B cells from pSS patients also had fewer IL-10(+) preswitched memory B cells. Moreover, TLR-7 and -9 stimulated B cells of pSS patients secreted increased amounts of several cytokines. B cells of pSS patients show a different responsiveness upon stimulation of TLR-7 and -9 compared to controls., (© 2015 The Foundation for the Scandinavian Journal of Immunology.)
- Published
- 2015
- Full Text
- View/download PDF
48. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).
- Author
-
Seror R, Theander E, Brun JG, Ramos-Casals M, Valim V, Dörner T, Bootsma H, Tzioufas A, Solans-Laqué R, Mandl T, Gottenberg JE, Hachulla E, Sivils KL, Ng WF, Fauchais AL, Bombardieri S, Valesini G, Bartoloni E, Saraux A, Tomsic M, Sumida T, Nishiyama S, Caporali R, Kruize AA, Vollenweider C, Ravaud P, Vitali C, Mariette X, and Bowman SJ
- Subjects
- Adult, Aged, Europe, Fatigue diagnosis, Fatigue etiology, Female, Humans, Male, Middle Aged, Pain diagnosis, Pain etiology, Prospective Studies, Reproducibility of Results, Severity of Illness Index, Sjogren's Syndrome complications, Sjogren's Syndrome diagnosis, Xerophthalmia diagnosis, Xerophthalmia etiology, Xerostomia diagnosis, Xerostomia etiology, Fatigue physiopathology, Pain physiopathology, Self Report, Sjogren's Syndrome physiopathology, Xerophthalmia physiopathology, Xerostomia physiopathology
- Abstract
Objectives: To validate the two recently developed disease activity indexes for assessment of primary Sjögren's syndrome (SS): the European League Against Rheumatism (EULAR) SS Patient Reported Index (ESSPRI) and the EULAR SS Disease Activity Index (ESSDAI)., Methods: A prospective international 6-month duration validation study was conducted in 15 countries. At each visit, physicians completed ESSDAI, SS disease activity index (SSDAI), Sjögren's Systemic Clinical Activity Index (SCAI) and physician global assessment (PhGA); and patients completed ESSPRI, Sicca Symptoms Inventory (SSI), Profile of Fatigue and Discomfort (PROFAD) and patient global assessment (PGA). Psychometric properties (construct validity, responsiveness and reliability) were evaluated and compared between scores., Results: Of the 395 patients included, 145 (37%) and 251 (64%) had currently active or current or past systemic manifestations, respectively. EULAR scores had higher correlation with the gold standard than other scores (ESSDAI with PhGA: r=0.59; ESSRPI with PGA: r=0.70). Correlations between patient and systemic scores were very low (ranging from 0.07 to 0.29). All systemic scores had similar large responsiveness in improved patients. Responsiveness of patient scores was low but was significantly higher for ESSPRI compared with SSI and PROFAD. Reliability was very good for all scores., Conclusions: ESSDAI and ESSPRI had good construct validity. All scores were reliable. Systemic scores had a large sensitivity to change in patients whose disease activity improves. Patient scores had a small sensitivity to change, however, significantly better for ESSPRI. Systemic and patient scores poorly correlated, suggesting that they are 2 complementary components that should be both evaluated, but separately., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.)
- Published
- 2015
- Full Text
- View/download PDF
49. High fidelity between saliva proteomics and the biologic state of salivary glands defines biomarker signatures for primary Sjögren's syndrome.
- Author
-
Delaleu N, Mydel P, Kwee I, Brun JG, Jonsson MV, and Jonsson R
- Subjects
- Adult, Aged, Arthritis, Rheumatoid diagnosis, Arthritis, Rheumatoid metabolism, Biomarkers metabolism, Clusterin metabolism, Female, Germinal Center metabolism, Humans, Interleukin-4 metabolism, Interleukin-5 metabolism, Middle Aged, Proteomics, Sjogren's Syndrome metabolism, Young Adult, Saliva metabolism, Salivary Glands metabolism, Sjogren's Syndrome diagnosis
- Abstract
Objective: Dependence on invasive procedures for classification of patients with Sjögren's syndrome (SS) hampers timely diagnosis and suitable patient followup. The aim of this study was to recapitulate the diagnosis of SS through noninvasive means and to define the biologic state of SS patients' salivary glands., Methods: Using a 187-plex capture antibody-based assay, salivary proteomic biomarker profiles were generated from patients with primary SS, patients with rheumatoid arthritis, and asymptomatic controls. Discriminant function analyses and Gene Ontology-based network analyses allowed data analyses with a reductionist approach and with a focus on systems biology., Results: Characterized by significant changes in 61 and 55 proteins, respectively, the salivary proteome of SS patients appeared profoundly altered compared to that of individuals without SS. On this basis, 4-plex and 6-plex biomarker signatures, both including interleukin-4 (IL-4), IL-5, and clusterin, achieved accurate prediction of an individual's group membership for at least 94% of cases. Of note, all misclassified SS patients presented with ectopic germinal center-like structures. Systematic inference of biologic meaning identified SS-related protein patterns delineating B cell-dominated immune responses, macrophage differentiation, and signs of T cell chemotaxis. In addition, proteomic Multi-Analyte Profiles provided insight about proteins related to collagen, cytokine, and growth factor synthesis as well as lipid transport., Conclusion: The SS-related molecular landscape conveyed by saliva showed great congruence with histopathologic features found in SS and advances understanding of this disease at a molecular level. Such salivary biomarker signatures harbor great potential for improving timeliness of SS diagnosis and enabling suitable patient followup., (Copyright © 2015 by the American College of Rheumatology.)
- Published
- 2015
- Full Text
- View/download PDF
50. Expression of Toll-like receptor -7 and -9 in B cell subsets from patients with primary Sjögren's syndrome.
- Author
-
Karlsen M, Hansen T, Nordal HH, Brun JG, Jonsson R, and Appel S
- Subjects
- Adult, Aged, B-Lymphocyte Subsets pathology, Case-Control Studies, Female, Humans, Male, Middle Aged, Receptors, CCR1 metabolism, Sjogren's Syndrome genetics, Sjogren's Syndrome pathology, Tumor Necrosis Factor Receptor Superfamily, Member 7 metabolism, Young Adult, B-Lymphocyte Subsets immunology, Sjogren's Syndrome immunology, Toll-Like Receptor 7 genetics, Toll-Like Receptor 7 metabolism, Toll-Like Receptor 9 genetics, Toll-Like Receptor 9 metabolism
- Abstract
Introduction: Sjögren's syndrome (SS) is a rheumatic autoimmune disease characterized by inflammation of exocrine glands. As autoantibodies are present in a majority of patients, B cells have been suggested to play an important role in onset and development of the disease. Toll-like receptors (TLRs) are pattern recognition receptors triggering innate immune responses. Since an increased expression of TLRs has been detected in other rheumatic diseases the purpose of this study was to explore TLRs in B cells of SS patients., Methods: The expression of TLR-7 and -9 in B cell subsets of 25 patients with primary SS (pSS) and 25 healthy controls was analysed in peripheral blood using flow cytometry and real time quantitative PCR., Results: We detected similar levels of CD19+ B cells in pSS patients and healthy controls. An increased number of naïve B cells, as well as fewer pre-switched memory B cells were found in pSS patients. No significant differences were observed in TLR-7 and -9 expression in B cells between pSS patients and healthy controls., Conclusion: This study shows that pSS patients have an alteration in the B cell subpopulation composition compared to controls, with less pre-switched memory B cells and more naïve B cells. We did not detect any significant disparities in TLR-7 and -9 expression between the two groups.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.